Modern complement analysis: Indications, methods and outlook;Moderne Komplementanalytik Indikationen - Methodik - Perspektiven

LaboratoriumsMedizin

Volumn 36, Issue 3, 2012, Pages 125-134

  Tudoran, Ruxandra ^a   Kirschfink, Michael ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

complement activation; complement analysis; complement system; immune defense

Indexed keywords

COMPLEMENT;

COMPLEMENT ACTIVATION; HOMEOSTASIS; HUMAN; INNATE IMMUNITY; MEDICAL PERSONNEL; MOLECULARLY TARGETED THERAPY; PROFESSIONAL KNOWLEDGE; PROTEIN ANALYSIS; REVIEW; TREATMENT INDICATION;

EID: 84861372037     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/labmed-2012-0003     Document Type: Review

References (55)

1. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, et al. Eculizumab in severe Shigatoxin-associated HUS. N Engl J Med 2011;364:2561-3.
2. Mollnes TE, Jokiranta TS, Truedsson L, Nilsson B, Rodriguez de Cordoba S, Kirschfink M. Complement analysis in the 21st century. Mol Immunol 2007;44:3838-49.
3. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: A key system for immune surveillance and homeostasis. Nat Immunol 2010;11:785-97.
4. Merino S, Nogueras MM, Aguilar A, Rubires X, Alberti S, Benedi VJ, et al. Activation of the complement classical pathway (C1q binding) by mesophilic Aeromonas hydrophila outer membrane protein. Infect Immun 1998;66:3825-31.
5. Turner MW. Mannose-binding lectin: The pluripotent molecule of the innate immune system. Immunol Today 1996;17:532-40.
6. Collard CD, Vakeva A, Morrissey MA, Agah A, Rollins SA, Reenstra WR, et al. Complement activation after oxidative stress: Role of the lectin complement pathway. Am J Pathol 2000;156:1549-56.
7. Sacks SH. Complement fragments C3a and C5a: The salt and pepper of the immune response. European J Immunol 2010;40:668-70.
8. Strey CW, Markiewski M, Mastellos D, Tudoran R, Spruce LA, Greenbaum LE, et al. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med 2003;198:913-23.
9. Gasque P, Singhrao SK, Neal JW, Wang P, Sayah S, Fontaine M, et al. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: Analysis in multiple sclerosis and bacterial meningitis. J Immunol 1998;160:3543-54.
10. European Society for Immunodeficiencies (ESID). Documented prevalence of PID in Europe. Available at: http://www.esid.org/statistics. Accessed 2012 April 1.
11. Zilow G, Joka T, Obertacke U, Rother U, Kirschfink M. Generation of anaphylatoxin C3a in plasma and bronchoalveolar lavage fluid in trauma patients at risk for the adult respiratory distress syndrome. Crit Care Med 1992;20:468-73.
12. Gerard C. Complement C5a in the sepsis syndrome-too much of a good thing ? N Engl J Med 2003;348:167-9.
13. Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol 2004;4:133-42.
14. Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): An update. J Am Soc Nephrol 2005;16:1392-403.
15. Proctor LM, Arumugam TV, Shiels I, Reid RC, Fairlie DP, Taylor SM. Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br J Pharmacol 2004;142:756-64.
16. Arumugam TV, Shiels IA, Woodruff TM, Granger DN, Taylor SM. The role of the complement system in ischemia-reperfusion injury. Shock 2004;21:401-9.
17. Karpel-Massler G, Fleming SD, Kirschfink M, Tsokos GC. Human C1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury. J Surg Res 2003;115:247-56.
18. Asgari E, Zhou W, Sacks S. Complement in organ transplantation. Current opinion in organ transplantation 2010;15:486-91.
19. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, et al. Arthritis critically dependent on innate immune system players. Immunity 2002;16:157-68.
20. Boos L, Campbell IL, Ames R, Wetsel RA, Barnum SR. Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis. J Immunol 2004;173:4708-14.
21. Eikelenboom P, Hack CE, Rozemuller JM, Stam FC. Complement activation in amyloid plaques in Alzheimer ' s dementia. Virchows Arch B Cell Pathol Incl Mol Pathol 1989;56: 259-62.
22. Laumonnier Y, Schmudde I, Kohl J. The role of complement in the diagnosis and management of allergic rhinitis and allergic asthma. Curr Aller Asthma Rep 2011;11:122-30.
23. Reca R, Mastellos D, Majka M, Marquez L, Ratajczak J, Franchini S, et al. Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood 2003;101:3784-93.
24. Markiewski MM, Mastellos D, Tudoran R, DeAngelis RA, Strey CW, Franchini S, et al. C3a and C3b activation products of the third component of complement (C3) are critical for normal liver recovery after toxic injury. J Immunol 2004;173: 747-54.
25. Botto M, Kirschfink M, Macor P, Pickering MC, Wurzner R, Tedesco F. Complement in human diseases: Lessons from complement deficiencies. Mol Immunol 2009;46:2774-83.
26. Sjoholm AG, Braconier JH, Soderstrom C. Properdin deficiency in a family with fulminant meningococcal infections. Clin Exp Immunol 1982;50:291-7.
27. Mollnes TE. Complement and biocompatibility. Vox Sanguinis 1998;74(Suppl 2):303-7.
28. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000;76:227-324.
29. Carroll MC. A protective role for innate immunity in systemic lupus erythematosus. Nat Rev Immunol 2004;4:825-31.
30. Cichon S, Martin L, Hennies HC, Muller F, Van Driessche K, Karpushova A, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. American J Hum Genet 2006;79:1098-104.
31. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 2009;373:759-67.
32. Nurnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009;360:542-4.
33. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Carreras Berges L, Lopez-Trascasa M, Sanchez-Corral P, et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005;14:703-12.
34. Licht C, Weyersberg A, Heinen S, Stapenhorst L, Devenge J, Beck B, et al. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 2005;45:415-21.
35. Khandhadia S, Cipriani V, Yates JR, Lotery AJ. Agerelated macular degeneration and the complement system. Immunobiology 2012;217:127-46.
36. Troutbeck R, Al-Qureshi S, Guymer RH. Therapeutic targeting of the complement system in age-related macular degeneration: A review. Clin Exp Ophthalmol 2012;40:18-26.
37. Serinsoz E, Bock O, Gwinner W, Schwarz A, Haller H, Kreipe H, et al. Local complement C3 expression is upregulated in humoral and cellular rejection of renal allografts. Am J Transplant 2005;5:1490-4.
38. Hecke F, Schmidt U, Kola A, Bautsch W, Klos A, Kohl J. Circulating complement proteins in multiple trauma patients-correlation with injury severity, development of sepsis, and outcome. Crit Care Med 1997;25:2015-24.
39. Huber-Lang MS, Riedeman NC, Sarma JV, Younkin EM, McGuire SR, Laudes IJ, et al. Protection of innate immunity by C5aR antagonist in septic mice. FASEB J 2002;16: 1567-74.
40. Riedemann NC, Guo RF, Neff TA, Laudes IJ, Keller KA, Sarma VJ, et al. Increased C5a receptor expression in sepsis. J Clin Invest 2002;110:101-8.
41. Selberg O, Hecker H, Martin M, Klos A, Bautsch W, Kohl J. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6. Crit Care Med 2000;28:2793-8.
42. Rother U. A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes. J Immunol Methods 1982;51:101-7.
43. Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002;195:211-20.
44. Cohen D, Colvin RB, Daha MR, Drachenberg CB, Haas M, Nickeleit V, et al. Pros and cons for C4d as a biomarker. Kidney Int 2012.
45. Seelen MA, Roos A, Wieslander J, Mollnes TE, Sjoholm AG, Wurzner R, et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: Standardization and validation of a simple ELISA. J Immunol Methods 2005;296:187-98.
46. Zilow G, Naser W, Rutz R, Burger R. Quantitation of the anaphylatoxin C3a in the presence of C3 by a novel sandwich ELISA using monoclonal antibody to a C3a neoepitope. J Immunol Methods 1989;121:261-8.
47. Stove S, Klos A, Bautsch W, Kohl J. Re-evaluation of the storage conditions for blood samples which are used for determination of complement activation. J Immunol Methods 1995; 182:1-5.
48. Sofat R, Casas JP, Webster AR, Bird AC, Mann SS, Yates JR, et al. Complement factor H genetic variant and age-related macular degeneration: Effect size, modifiers and relationship to disease subtype. Int J Epidemiol 2012.
49. Raychaudhuri S, Iartchouk O, Chin K, Tan PL, Tai AK, Ripke S, et al. A rare penetrant mutation in CFH confers high risk of agerelated macular degeneration. Nat Genet 2011;43:1232-6.
50. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011;7:23-35.
51. Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: Roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 2004;25:5681-703.
52. Kourtzelis I, Markiewski MM, Doumas M, Rafail S, Kambas K, Mitroulis I, et al. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood 2010;116:631-9.
53. Ferraz N, Ott MK, Hong J. Time sequence of blood activation by nanoporous alumina: Studies on platelets and complement system. Micro Res Tech 2010;73:1101-9.
54. Mollnes TE, Kirschfink M. Strategies of therapeutic complement inhibition. Mol Immunol 2006;43:107-21.
55. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol 2007;25:1265-75.